2 型糖尿病
寿险:
- 标准
- 加费
- 除外(通常不出现)
- 延期(通常不出现)
- 拒保
重疾:
- 标准(通常不出现)
- 加费
- 除外(通常不出现)
- 延期(通常不出现)
- 拒保
GLP-1 受体激动剂
用于 2 型糖尿病(Ozempic、Rybelsus)与体重管理(Wegovy)。
核保会先问「为什么用」:治糖尿病就按糖尿病评估;减重用就看用药前后体重与是否稳定,有的公司按用药前体重或要求稳定一段时间。
寿险:
重疾:
寿险:
重疾:
寿险:
重疾:
把病名、确诊日期、用药与剂量、最近检查结果带给持牌顾问,请他先做预审再正式投保。
各公司核保不同,以核保结果为准。本页是一般信息,不是个人医疗或投保建议;病与药的介绍只引官方来源。
先看导读,再看图;点图放大、左右翻页,每张卡都有可分享的详情页。卡上每个字都出自本站正文,不列费率。

价格是个人化的
保费按年龄、性别、是否吸烟和健康状况报价,本站不列费率。持牌保险顾问可在多家公司之间比较报价(可报价的公司以其签约为准),把条款差异列在同一页上。
询价前要准备什么 →Health and insurability atlas / By medication
GLP-1 receptor agonist
Semaglutide
Used for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy).
Underwriters first ask why it is used: for diabetes it is assessed as diabetes; for weight loss they look at weight before and after and its stability — some insurers use pre-treatment weight or want a period of stable weight.
Life:
Critical illness:
Life:
Critical illness:
Life:
Critical illness:
Bring the condition, diagnosis date, medications and doses, and recent test results to a licensed advisor and ask for a pre-assessment before a formal application.
Underwriting differs by insurer; the insurer’s decision is final. General information only, not personal medical or insurance advice; condition and medication descriptions cite official sources.